A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting
Clinical trial NCT01808573 · COMPLETED
Trial details
- NCT number
- NCT01808573
- Sponsor
- Puma Biotechnology, Inc.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2013-03-29
- Primary completion
- 2018-09-28
- Enrollment
- 621
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.